Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan vs Esomeprazole for Nighttime Heartburn in GERD
NCT05701540Phase 4Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tegoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by HK inno.N Corporation. Primary endpoint: Percentage of days without nighttime heartburn during the 2-week dosing period. Status: unknown.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05701540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701540.